title: Intraoperative high-dose-rate radiotherapy in the management of locoregionally recurrent head and neck cancer.
abstract: BACKGROUND
  The purpose of this article was to present the Beth Israel Medical Center experience using high-dose-rate intraoperative radiotherapy (HDR-IORT) in the management of recurrent head and neck cancer.
  
  
  METHODS
  We conducted a retrospective review of all patients with locally or regionally recurrent head and neck cancer who underwent HDR-IORT at our institution between 2001 and 2010.
  
  
  RESULTS
  Seventy-six patients were identified who underwent treatment to a total of 87 sites after gross-total resection. The 2-year estimate of in-field tumor control was found to be 62%. Median overall survival was 19 months with 42% of the patients surviving at least 2 years. Significantly longer survival was found for patients achieving in-field control versus infield progression (33 months vs 17 months, respectively; p = .01).
  
  
  CONCLUSIONS
  HDR-IORT is well tolerated and associated with encouraging in-field disease control. In-field control is associated with improved survival. Further study is warranted to more fully investigate HDR-IORT in the salvage setting.
authors: Department of Radiation Oncology, Beth Israel Medical Center - Continuum Cancer Centers of New York, USA.
authors: L Matthew
authors: LM
authors: Scala
authors: Kenneth
authors: K
authors: Hu
authors: Mark L
authors: ML
authors: Urken
authors: Adam S
authors: AS
authors: Jacobson
authors: Mark S
authors: MS
authors: Persky
authors: Theresa N
authors: TN
authors: Tran
authors: Mark L
authors: ML
authors: Smith
authors: Stimson
authors: S
authors: Schantz
authors: Louis B
authors: LB
authors: Harrison
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006258:Head and Neck Neoplasms / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D006801:Humans; D007432:Intraoperative Period; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000532:radiotherapy*; D011379:Prognosis; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome; D055815:Young Adult